- Belinostat Impurity
-
- $0.00 / 10mg
-
2025-05-09
- CAS:866323-14-0
- Min. Order: 10mg
- Purity: 95%+
- Supply Ability: 10000000
- Belinostat
-
- $40.00 / 5mg
-
2025-05-06
- CAS:866323-14-0
- Min. Order:
- Purity: 99.75%
- Supply Ability: 10g
- PXD-101
-
- $1.00 / 1KG
-
2019-07-06
- CAS:866323-14-0
- Min. Order: 1KG
- Purity: 98-100%
- Supply Ability: 100KG
|
| | PXD-101 Basic information |
| Product Name: | PXD-101 | | Synonyms: | (2E)-N-Hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-2-propenamide;2-PropenaMide, N-hydroxy-3-[3-[(phenylaMino)sulfonyl]phenyl]-, (2E)-;Belista;PXD101;PX105684;PXD-101;PXD 101;PX-105684;Belinostat（E）;3-[3-(phenylsulfamoyl)phenyl]prop-2-enehydroxamic acid;(e)-n-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide;Belinostat Impurity | | CAS: | 866323-14-0 | | MF: | C15H14N2O4S | | MW: | 318.35 | | EINECS: | | | Product Categories: | | | Mol File: | 866323-14-0.mol |  |
| | PXD-101 Chemical Properties |
| Melting point | 172 °C(Solv: ethyl acetate (141-78-6)) | | density | 1.427±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMSO:64.0(Max Conc. mg/mL);201.4(Max Conc. mM) | | form | powder to crystal | | pka | 8.27±0.10(Predicted) | | color | White to Light yellow to Light orange |
| | PXD-101 Usage And Synthesis |
| Uses | Belinostat (PXD101; PX105684) is a potent HDAC inhibitor with an IC50 of 27 nM in HeLa cell extracts. | | Definition | ChEBI: Belinostat is a hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. It has a role as an antineoplastic agent and an EC 3.5.1.98 (histone deacetylase) inhibitor. It is a hydroxamic acid, a sulfonamide and an olefinic compound. | | Biological Activity | Belinost at (PX105684; PXD101) is a potent, hydroxamate class pan-selective histone deacetylases (HDACs) inhibitor (IC50: class I HDAC1/2/3/8 = 41/125/30/216 nM, class IIA HDAC4/7/9 = 115/67/128 nM, class IIB HDAC6 = 82 nM) with anti-cancer efficacy in vitro and in vivo. | | in vivo | Treatment of nude mice bearing human ovarian and colon tumor xenografts with Belinostat (10-40 mg/kg/day i.p.) daily for 7 days causes a significant dose-dependent growth delay with no obvious signs of toxicity to the mice. Growth delay is also observed for xenografts of cisplatin-resistant ovarian tumor cells. A marked increase in acetylation of H4 is detected in blood and tumor of mice 3 h after treatment with Belinostat (PXD101). The inhibition of growth of human tumor xenografts in mice, with no apparent toxicity[1]. Belinostat (PXD101) displays single-agent antitumor activity on human A2780 ovarian cancer s.c. xenografts which is enhanced via combination therapy with Carboplatin[2]. | | IC 50 | HDAC6: 82 nM (IC50); HDAC: 27 nM (IC50, Hela cell) | | References | [1] Plumb JA, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histonedeacetylase inhibitor PXD101. Mol Cancer Ther. 2003 Aug;2(8):721-8. PMID:12939461
[2] Qian X, et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther. 2006 Aug;5(8):2086-95. DOI:10.1158/1535-7163.MCT-06-0111
[3] Chia S, et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017 Sep 5;8(1):435. DOI:10.1038/s41467-017-00451-5 |
| | PXD-101 Preparation Products And Raw materials |
|